PharmaTimes

About PharmaTimes

PharmaTimes is a UK-based pharmaceutical industry publication serving the life sciences sector from Little Bookham, Surrey. Published by PharmaTimes Media Ltd, it combines a daily news website with a monthly print and digital magazine, covering drug development, regulatory decisions, market access and the business of pharma for an audience of industry professionals. Visit the official website at pharmatimes.com.

History and founding

PharmaTimes was established as a specialist business-to-business title for the pharmaceutical industry, building a print magazine and later a digital news operation serving the UK and international life sciences community. Published by PharmaTimes Media Ltd from Mansard House, Church Road, Little Bookham, Surrey, the title has grown into a recognised voice in pharma trade media, with a claimed circulation of 19,000. Its development mirrors the pharmaceutical industry's own globalisation: from a UK-focused trade magazine to a daily news service tracking drug approvals and clinical developments worldwide.

Ownership and funding model

PharmaTimes is owned and published by PharmaTimes Media Ltd, an independent specialist publisher based in Little Bookham, Surrey (KT23 3JG). The company operates a classic B2B publishing model: the magazine is available in digital and paper formats, free to qualifying readers via subscription, and funded by advertising and commercial partnerships with pharmaceutical companies, service providers and industry suppliers. Its sales and marketing operation is led by business director Tara Lovegrove and business manager Luci Sargood.

Editorial focus and coverage areas

PharmaTimes covers the pharmaceutical and biotechnology industries across the full product lifecycle: clinical trial results, regulatory milestones (FDA approvals, EMA opinions, NICE guidance, CHMP recommendations), licensing deals and M&A, market access and pricing, and the business strategies of the major drugmakers. Its 2026 news output illustrates the beat — stories on novel CAR-T therapies for multiple myeloma, orphan drug designations, FDA fast-track awards, Alzheimer's drug collaborations, biosimilar applications and gene therapy trials. The monthly magazine carries longer features, interviews and analysis, with the editor's column setting the tone on industry issues from clinical trial diversity to the industry's pandemic legacy.

Notable journalists and contributors

PharmaTimes' editorial team is led by editor John Pinching, with Iona Everson as group managing editor and Karl Equi as executive director. Pinching's editorials — covering topics from gender disparity in the industry to the lessons of COVID-19 for pharma's public standing — give the title a distinctive voice in trade media. The team's journalism serves a specialist professional readership that demands accuracy on complex scientific and regulatory subjects.

Audience and reach

PharmaTimes serves professionals across the pharmaceutical and life sciences industries: executives, marketers, market-access specialists, regulatory affairs professionals and service providers. The title claims a circulation of 19,000, and its daily website extends its reach to a global audience of industry readers tracking drug development news. Its readership includes the decision-makers at pharma companies and the agencies, consultancies and suppliers that serve them.

Business model

PharmaTimes operates a B2B publishing model built on controlled-circulation print, digital advertising, sponsored content and commercial partnerships. The magazine is free to qualifying industry readers, with revenue coming from the pharmaceutical companies and suppliers who advertise to reach them. Digital and paper subscriptions, reprints and event-related activity add further revenue strands.

Digital platforms, podcasts and newsletters

PharmaTimes publishes daily news through pharmatimes.com, with paginated news archives tracking the industry's developments day by day, and produces a digital edition of its monthly magazine via magazine.pharmatimes.com. The title maintains an active social media presence (@PharmaTimes) and offers email subscriptions for news updates. Its digital operation complements the print magazine, giving readers both breaking news online and in-depth analysis in the monthly issue.

Awards and recognition

PharmaTimes is an established brand in pharmaceutical trade media, recognised within the industry as a source of daily news and monthly analysis. Its longevity and its claimed circulation of 19,000 attest to its position in the market, and its editorial is read across the UK pharma industry and beyond.

Industry role and reputation

PharmaTimes functions as a trade paper for the pharmaceutical industry: the daily record of approvals, trials and deals, and the monthly forum for analysis and debate. Its editorials tackle the industry's relationship with wider society — from diversity in clinical trials to pharma's role in ending the pandemic — positioning the title as a thoughtful industry insider rather than a mere news feed.

Outlook

PharmaTimes continues to publish daily news and its monthly magazine from Little Bookham, covering an industry being reshaped by AI-driven drug discovery, advanced therapies and changing market-access dynamics. As the pharmaceutical sector navigates these shifts, the title's combination of daily news and monthly analysis keeps it relevant to the professionals steering the industry.

The magazine and the editor's voice

What distinguishes PharmaTimes from purely digital pharma news sites is its monthly magazine — a print and digital publication that gives the title a slower, more reflective register alongside its daily news feed. The magazine carries in-depth features, interviews with industry leaders and analysis of the strategic questions facing pharma, from R&D productivity to market access and the industry's social licence. Its front-of-book editorials, written by editor John Pinching, are among the most distinctive voices in pharmaceutical trade media: wide-ranging columns that connect industry developments to wider cultural and political currents. Pinching has used the column to argue for greater diversity in clinical trials — warning against "box-ticking" approaches to inclusion and insisting that difference produces better science and better business — and to reflect on pharma's pandemic legacy, crediting "the unheralded lab crews of these fair isles" for the return to normality and arguing that the industry has never been properly recognised as, in his phrase, the "freedom fighter of the pandemic story." The editorials move fluidly between industry analysis and cultural commentary, citing everything from Ghostbusters to Professor Sarah Gilbert, and they give the magazine a personality rare in B2B publishing. The magazine's production values — its design, photography and long-form journalism — position it as the premium product in PharmaTimes Media's portfolio, while the daily website handles the news cycle. For readers, the two products serve different needs: the website for the day's approvals, trial readouts and deals; the magazine for the monthly step back. The company's Little Bookham base, in the Surrey commuter belt rather than central London, reflects its independent character — a specialist publisher serving a global industry from a village office. Under Pinching's editorship, with Iona Everson as group managing editor, the title has maintained a consistent identity: scientifically literate, commercially aware and willing to speak plainly about the industry's challenges.

PharmaTimes Media's independence and its Little Bookham base are part of the title's character. Operating from Mansard House on Church Road rather than a London media tower, the company exemplifies the specialist B2B publisher: small, focused and deeply embedded in its sector. The qualifying-reader model — free print and digital copies for industry professionals who meet circulation criteria — is the classic controlled-circulation formula, aligning the title's interests with its audience rather than with newsstand sales. Editor John Pinching's long tenure has given the magazine a consistent voice, and the team's stability, from group managing editor Iona Everson to the commercial side led by Tara Lovegrove, reflects a business built for the long term. As pharmaceutical marketing and communications continue to fragment across channels, the trade title that can combine daily news with monthly authority — and speak plainly to its industry — retains a clear role.